



CORRECTION

Correction to: Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization

Dominique Hubert · Christophe Marguet · Jacques Benichou ·
Cynthia DeSouza · Catherine Payen-Champenois · Nils Kinnman ·
Keval Chandarana · Anne Munck · Isabelle Fajac on behalf of the BRIO Study Group

Published online: July 14, 2021
© The Author(s) 2021

Correction to: Pulm Ther
<https://doi.org/10.1007/s41030-021-00158-5>

The original version of this article unfortunately contained a mistake. In the “Results” section of the abstract, the word “post-ivacaftor” was misspelled and should replace the word “post-fivacaftor”. The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s41030-021-00158-5>.

D. Hubert (✉) · I. Fajac
Respiratory Medicine and National Cystic Fibrosis
Reference Center, Cochin Hospital, Assistance
Publique-Hôpitaux de Paris, Paris, France
e-mail: dominique.hubert@aphp.fr

C. Marguet
Pediatric Respiratory Diseases and Cystic Fibrosis
Center, Rouen University Hospital, INSERM
CIC1404, EA 2656 UNI ROUEN, Normandy
University, Rouen, France
e-mail: christophe.marguet@chu-rouen.fr

J. Benichou
Department of Biostatistics and Clinical Research,
Rouen University Hospital and INSERM U 1018,
University of Rouen, Rouen, France
e-mail: jacques.benichou@chu-rouen.fr

C. DeSouza
Independent Consultant, Boston, MA, USA
e-mail: cynthia.desouza4@gmail.com

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are

C. Payen-Champenois
Vertex Pharmaceuticals (France), Paris, France
e-mail: catherine_payen-champenois@vrtx.com

N. Kinnman
Vertex Pharmaceuticals (Europe) Limited, London,
UK
e-mail: nils_kinnman@vrtx.com

K. Chandarana
Vertex Pharmaceuticals Incorporated, Boston, MA,
USA
e-mail: keval_chandarana@vrtx.com

A. Munck
Cystic Fibrosis Center, Hôpital Robert Debré,
Assistance Publique-Hôpitaux de Paris, Paris, France
e-mail: anne.munck1@gmail.com

I. Fajac
Physiology Department, AP-HP Centre-Université
de Paris, Hôpital Cochin, Paris, France
e-mail: isabelle.fajac@parisdescartes.fr

included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory

regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.